Pfizer to Present Landmark Survival Data for Cancer Therapies at ASCO GU 2025 Symposium
Key Insights
Pfizer will showcase over 20 abstracts at ASCO GU (search) 2025, including pivotal Phase 3 TALAPRO-2 (search) trial results demonstrating significant overall survival benefits for TALZENNA-XTANDI combination in prostate cancer.
Updated analysis from Phase 3 EV-302 (search) trial confirms sustained survival advantage of PADCEV with pembrolizumab in advanced urothelial cancer (search), reinforcing its position as a first-line treatment standard.
Novel investigational therapy mevrometostat shows promising progression-free survival data when combined with XTANDI in metastatic castration-resistant prostate cancer (search), advancing Pfizer's genitourinary cancer pipeline.
Pfizer Inc. is set to present significant advances in genitourinary cancer treatment at the upcoming American Society of Clinical Oncology Genitourinary (ASCO GU (search)) Cancers Symposium, taking place February 13-15 in San Francisco. The company will showcase data from more than 20 research abstracts, including five oral presentations, highlighting progress across their prostate and bladder cancer portfolio.
Breakthrough Results in Prostate Cancer Treatment
The spotlight will be on the detailed overall survival (OS) results from the Phase 3 TALAPRO-2 (search) trial, which has been selected for ASCO GU (search)'s official Press Program. The study evaluated TALZENNA® (talazoparib) in combination with XTANDI® (enzalutamide) in patients with metastatic castration-resistant prostate cancer (search) (mCRPC). The combination therapy demonstrated statistically significant and clinically meaningful improvement in overall survival compared to XTANDI alone, both in the general patient population and in those with homologous recombination repair (HRR) gene mutations.
"Our long-standing commitment to the genitourinary cancer community has been foundational in our mission to transform the treatment landscapes for patients with bladder and prostate cancers," said Karin Tollefson, Chief Oncology Medical Officer at Pfizer.
Advancing Bladder Cancer Treatment Options
A key highlight includes updated analysis from the Phase 3 EV-302 (search) study, which continues to demonstrate the sustained efficacy of PADCEV® (enfortumab vedotin-ejfv) in combination with pembrolizumab for patients with locally advanced or metastatic urothelial cancer (search). The long-term follow-up data reinforces this combination's position as a standard of care in first-line treatment.
Innovation in Pipeline Development
The symposium will feature the first randomized progression-free survival (PFS) data for mevrometostat (PF-06821497), Pfizer's investigational EZH2 inhibitor, in combination with XTANDI. This early data has already prompted the initiation of two pivotal Phase 3 trials in 2024, with another planned for early 2025.
Expanding Research in Multiple Directions
Additional presentations will showcase Pfizer's comprehensive approach to genitourinary cancers:
- Six abstracts supporting XTANDI's benefits across approved indications
- Updated efficacy data for disitamab vedotin, an investigational HER2-targeting antibody-drug conjugate
- Real-world evidence highlighting treatment patterns and unmet needs in non-muscle invasive bladder cancer
Future Implications
With seven approved medicines across bladder, prostate, and kidney cancers, Pfizer continues to strengthen its position in genitourinary oncology. The company's growing pipeline spans multiple scientific modalities, including small molecules, antibody-drug conjugates, and novel combination approaches, demonstrating their commitment to addressing diverse patient needs across various disease stages.
The breadth of data being presented underscores Pfizer's comprehensive approach to advancing cancer care through scientific innovation and clinical research. These developments suggest potential new treatment options for patients with genitourinary cancers, particularly those with limited therapeutic alternatives.